SEC Form 3 · accession 0001104659-18-046097
Replimune Group, Inc. · REPL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Colin Love
Officer — Chief Operating Officer · 10% Owner
Period of report
Jul 19, 2018
Accepted (ET)
Jul 19, 2018 · 8:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001737953
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 1,119,024 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $3.30 | holding | — | — | — | — | Jul 26, 2027 | Common Stock | 149,203 | — | D |
Explanation of responses
- F1Does not include 26,258 shares of the Issuer's common A stock held by Dr. Love, which will be repurchased by the Issuer and cancelled immediately prior to the completion of the Issuer's proposed initial public offering.
- F225% of the shares underlying this stock option vest on July 26, 2018 and the remainder of the shares underlying this stock option vest in 36 equal monthly installments thereafter.
Remarks
Exhibit List Exhibit 24 - Power of Attorney